-
1
-
-
0000772523
-
Triple oral antidiabetic therapy in type 2 diabetes mellitus
-
Ovalle F, Bell DS. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998; 4: 146-7.
-
(1998)
Endocr Pract
, vol.4
, pp. 146-147
-
-
Ovalle, F.1
Bell, D.S.2
-
2
-
-
33745000699
-
Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients
-
Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care. 2006; 29: 554-9.
-
(2006)
Diabetes Care
, vol.29
, pp. 554-559
-
-
Rosenstock, J.1
Sugimoto, D.2
Strange, P.3
Stewart, J.A.4
Soltes-Rak, E.5
Dailey, G.6
-
3
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB et al.Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
4
-
-
79960796303
-
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II)
-
Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab. 2011; 13: 800-5.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 800-805
-
-
Bell, D.S.1
Dharmalingam, M.2
Kumar, S.3
Sawakhande, R.B.4
-
5
-
-
64749110344
-
Hypoglycemia: Still the limiting factor in the glycemic management of diabetes
-
Cryer PE. Hypoglycemia: Still the limiting factor in the glycemic management of diabetes. Endocr Pract. 2008; 14: 750-6.
-
(2008)
Endocr Pract
, vol.14
, pp. 750-756
-
-
Cryer, P.E.1
-
6
-
-
0041736553
-
Metformin: New understandings, new uses
-
Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs. 2003; 63: 1879-94.
-
(2003)
Drugs
, vol.63
, pp. 1879-1894
-
-
Hundal, R.S.1
Inzucchi, S.E.2
-
7
-
-
77957710722
-
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents
-
Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs. 2010; 70: 1945-61.
-
(2010)
Drugs
, vol.70
, pp. 1945-1961
-
-
Derosa, G.1
-
8
-
-
79961222810
-
Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
-
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs. 2011; 71: 1441-67.
-
(2011)
Drugs
, vol.71
, pp. 1441-1467
-
-
Baetta, R.1
Corsini, A.2
-
9
-
-
33749871472
-
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
-
Herman GA, Bergman A, Stevens C et al.Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91: 4612-9.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 4612-4619
-
-
Herman, G.A.1
Bergman, A.2
Stevens, C.3
-
10
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-57.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
11
-
-
0035097211
-
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
-
Mannucci E, Ognibene A, Cremasco F et al.Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24: 489-94.
-
(2001)
Diabetes Care
, vol.24
, pp. 489-494
-
-
Mannucci, E.1
Ognibene, A.2
Cremasco, F.3
-
12
-
-
78449274342
-
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
-
Migoya EM, Bergeron R, Miller JL et al.Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010; 88: 801-8.
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 801-808
-
-
Migoya, E.M.1
Bergeron, R.2
Miller, J.L.3
-
13
-
-
33845476757
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Sitagliptin Study 020 Group.
-
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29: 2638-43.
-
(2006)
Diabetes Care
, vol.29
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
14
-
-
39749184723
-
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
-
Raz I, Chen Y, Wu M et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008; 24: 537-50.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 537-550
-
-
Raz, I.1
Chen, Y.2
Wu, M.3
-
15
-
-
34547660561
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
-
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1979-87.
-
(2007)
Diabetes Care
, vol.30
, pp. 1979-1987
-
-
Goldstein, B.J.1
Feinglos, M.N.2
Lunceford, J.K.3
Johnson, J.4
Williams-Herman, D.E.5
-
16
-
-
23744434472
-
Rosiglitazone/metformin
-
Wellington K. Rosiglitazone/metformin. Drugs. 2005; 65: 1581-92.
-
(2005)
Drugs
, vol.65
, pp. 1581-1592
-
-
Wellington, K.1
-
17
-
-
34548316762
-
Pioglitazone and metformin
-
Hill NR, Matthews DR. Pioglitazone and metformin. Drugs Today. 2007; 43: 443-54.
-
(2007)
Drugs Today
, vol.43
, pp. 443-454
-
-
Hill, N.R.1
Matthews, D.R.2
-
18
-
-
33751557143
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
-
Sitagliptin Study 019 Group.
-
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-68.
-
(2006)
Clin Ther
, vol.28
, pp. 1556-1568
-
-
Rosenstock, J.1
Brazg, R.2
Andryuk, P.J.3
Lu, K.4
Stein, P.5
-
19
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
Aschner P, Kipnes MS, Lunceford JK et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29: 2632-7.
-
(2006)
Diabetes Care
, vol.29
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
-
20
-
-
0021813187
-
Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
-
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
-
(1985)
Diabetologia
, vol.28
, pp. 412-419
-
-
Matthews, D.R.1
Hosker, J.P.2
Rudenski, A.S.3
Naylor, B.A.4
Treacher, D.F.5
Turner, R.C.6
-
21
-
-
0034456568
-
Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
-
Katz A, Nambi SS, Mather K et al.Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85: 2402-10.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 2402-2410
-
-
Katz, A.1
Nambi, S.S.2
Mather, K.3
-
22
-
-
0026793272
-
Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance
-
Yoneda H, Ikegami H, Yamamoto Y et al.Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care. 1992; 15: 1517-21.
-
(1992)
Diabetes Care
, vol.15
, pp. 1517-1521
-
-
Yoneda, H.1
Ikegami, H.2
Yamamoto, Y.3
-
23
-
-
0032580377
-
Interval estimation for the difference between independent proportions: Comparison of eleven methods
-
Newcombe RG. Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med. 1998; 17: 873-90.
-
(1998)
Stat Med
, vol.17
, pp. 873-890
-
-
Newcombe, R.G.1
-
25
-
-
28444440888
-
Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study
-
Bailey CJ, Bagdonas A, Rubes J et al.Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005; 27: 1548-61.
-
(2005)
Clin Ther
, vol.27
, pp. 1548-1561
-
-
Bailey, C.J.1
Bagdonas, A.2
Rubes, J.3
-
26
-
-
33749498694
-
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
-
Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006; 8: 650-60.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 650-660
-
-
Rosenstock, J.1
Rood, J.2
Cobitz, A.3
Biswas, N.4
Chou, H.5
Garber, A.6
-
27
-
-
69549135336
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
-
DeFronzo RA, Hissa MN, Garber AJ et al.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649-55.
-
(2009)
Diabetes Care
, vol.32
, pp. 1649-1655
-
-
DeFronzo, R.A.1
Hissa, M.N.2
Garber, A.J.3
-
28
-
-
78751562877
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
-
Yoon KH, Shockey GR, Teng R et al.Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011; 65: 154-64.
-
(2011)
Int J Clin Pract
, vol.65
, pp. 154-164
-
-
Yoon, K.H.1
Shockey, G.R.2
Teng, R.3
-
29
-
-
77951069227
-
Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10246 patients with type 2 diabetes
-
Williams-Herman D, Engel SS, Round E et al.Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10246 patients with type 2 diabetes. BMC Endocr Disord. 2010; 10: 7.
-
(2010)
BMC Endocr Disord
, vol.10
, pp. 7
-
-
Williams-Herman, D.1
Engel, S.S.2
Round, E.3
-
30
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
-
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298: 194-206.
-
(2007)
JAMA
, vol.298
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
32
-
-
34547161425
-
A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies
-
Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies. Curr Med Res Opin. 2007; 23: 1493-507.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 1493-1507
-
-
Barnett, A.1
Allsworth, J.2
Jameson, K.3
Mann, R.4
-
33
-
-
0036250329
-
Differentiating members of the thiazolidinedione class: A focus on safety
-
Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev. 2002; 18(Suppl. 2): S23-9.
-
(2002)
Diabetes Metab Res Rev
, vol.18
, Issue.SUPPL. 2
-
-
Lebovitz, H.E.1
-
34
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71.
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
35
-
-
54349120809
-
Cardiotoxic drugs: Clinical monitoring and decision making
-
Wu AH. Cardiotoxic drugs: Clinical monitoring and decision making. Heart. 2008; 94: 1503-9.
-
(2008)
Heart
, vol.94
, pp. 1503-1509
-
-
Wu, A.H.1
-
36
-
-
77957952617
-
Regulatory action on rosiglitazone by the U.S. Food and Drug Administration
-
Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med. 2010; 363: 1489-91.
-
(2010)
N Engl J Med
, vol.363
, pp. 1489-1491
-
-
Woodcock, J.1
Sharfstein, J.M.2
Hamburg, M.3
|